
    
      This prospective observational study of the Greek population to approximately 2,500 patients
      suffering from asthma, aims to collect the characteristics of patients that were selected to
      obtain an inhaled combination of budesonide and formoterol fumarate dihydrate in any of
      portions 100 / 6mcg, 200 / 6mcg, 400/12 mcg (Pulmoton®), and to collect data on the quality
      of life to such an inhaled combination through Elpenhaler® device.

      Data will be collected for a period of three months from patients diagnosed with asthma not
      adequately controlled with inhaled corticosteroids and 'as needed' inhaled beta2-agonists
      short-acting or patients already adequately controlled on both inhaled corticosteroids and
      long-acting beta2-agonists.

      Data will be collected during the period of one (1) to three (3) months (± 2 weeks) from the
      initiation of treatment with inhaled combination include ACQ checklist questionnaire mini
      AQLQ, questionnaire FSI 10, and data any existing comorbidities.
    
  